Tirzepatide, targeting both GLP1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, gained T2DM approval in 2022 and is currently undergoing evaluation for obesity indications [6]. Here, GLP1R is linked to type 2 diabetes mellitus.